Table 3.
Spearman’s correlation of CTCs and serum biomarkers with OS and PFS.
| OS | PFS | |
|---|---|---|
| Spearman’s ρ (p-value) | ||
| mCRPC patients | ||
| Total-CTCs | -0.66 (0.0027) | -0.52 (0.075) |
| Epithelial-CTCs | -0.62 (0.0057) | -0.63 (0.0049) |
| EMTing-CTCs | -0.65 (0.0034) | -0.14 (0.57) |
| Mesenchymal-CTCs | -0.40 (0.10) | 0.34 (0.17) |
| CTC-score | -0.80 (<0.0001) | -0.65 (0.0033) |
| PSA | -0.72 (0.0008) | -0.50 (0.035) |
| ALP | -0.41 (0.13) | -0.16 (0.55) |
| mHSPC patients | ||
| Total-CTCs | 0.16 (0.31) | -0.087 (0.58) |
| Epithelial-CTCs | -0.084 (0.60) | -0.16 (0.30) |
| EMTing-CTCs | 0.13 (0.41) | 0.11 (0.43) |
| Mesenchymal-CTCs | 0.20 (0.20) | -0.076 (0.63) |
| CTC-score | 0.012 (0.94) | -0.18 (0.26) |
| PSA | -0.21 (0.19) | -0.16 (0.33) |
| ALP | -0.45 (0.0068) | -0.62 (<0.0001) |
PFS, progression-free survival; OS, overall survival; bold black numbers, significant results